Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers

Metaplastic breast cancer (MBC) is a rare form of breast cancer characterized by an aggressive clinical presentation, with a poor response to standard chemotherapy. MBCs are typically triple-negative breast cancers (TNBCs), frequently with alterations to genes of the PI3K-AKT-mTOR and RTK-MAPK signa...

Full description

Saved in:
Bibliographic Details
Published inJournal of hematology and oncology Vol. 13; no. 1; pp. 13 - 10
Main Authors Coussy, F, El Botty, R, Lavigne, M, Gu, C, Fuhrmann, L, Briaux, A, de Koning, L, Dahmani, A, Montaudon, E, Morisset, L, Huguet, L, Sourd, L, Painsec, P, Chateau-Joubert, S, Larcher, T, Vacher, S, Melaabi, S, Salomon, A Vincent, Marangoni, E, Bieche, I
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 22.02.2020
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Metaplastic breast cancer (MBC) is a rare form of breast cancer characterized by an aggressive clinical presentation, with a poor response to standard chemotherapy. MBCs are typically triple-negative breast cancers (TNBCs), frequently with alterations to genes of the PI3K-AKT-mTOR and RTK-MAPK signaling pathways. The objective of this study was to determine the response to PI3K and MAPK pathway inhibitors in patient-derived xenografts (PDXs) of MBCs with targetable alterations. We compared survival between triple-negative MBCs and other histological subtypes, in a clinical cohort of 323 TNBC patients. PDX models were established from primary breast tumors classified as MBC. PI3K-AKT-mTOR and RTK-MAPK pathway alterations were detected by targeted next-generation sequencing (NGS) and analyses of copy number alterations. Activation of the PI3K-AKT-mTOR and RTK-MAPK signaling pathways was analyzed with reverse-phase protein arrays (RPPA). PDXs carrying an activating mutation of PIK3CA and genomic changes to the RTK-MAPK signaling pathways were treated with a combination consisting of a PI3K inhibitor and a MEK inhibitor. In our clinical cohort, the patients with MBC had a worse prognosis than those with other histological subtypes. We established nine metaplastic TNBC PDXs. Three had a pathogenic mutation of PIK3CA and additional alterations to genes associated with RTK-MAPK signaling. The MBC PDXs expressed typical EMT and stem cell genes and were of the mesenchymal or mesenchymal stem-like TNBC subtypes. On histological analysis, MBC PDXs presented squamous or chondroid differentiation. RPPA analysis showed activation of the PI3K-AKT-mTOR and RTK-MAPK signaling pathways. In vivo, the combination of PI3K and MAPK inhibitors displayed marked antitumor activity in PDXs carrying genomic alterations of PIK3CA, AKT1, BRAF, and FGFR4. The treatment of metaplastic breast cancer PDXs by activation of the PI3K-AKT-mTOR and RTK-MAPK pathways at the genomic and protein levels with a combination of PI3K and MEK inhibitors resulted in tumor regression in mutated models and may therefore be of interest for therapeutic purposes.
AbstractList Background Metaplastic breast cancer (MBC) is a rare form of breast cancer characterized by an aggressive clinical presentation, with a poor response to standard chemotherapy. MBCs are typically triple-negative breast cancers (TNBCs), frequently with alterations to genes of the PI3K-AKT-mTOR and RTK-MAPK signaling pathways. The objective of this study was to determine the response to PI3K and MAPK pathway inhibitors in patient-derived xenografts (PDXs) of MBCs with targetable alterations. Methods We compared survival between triple-negative MBCs and other histological subtypes, in a clinical cohort of 323 TNBC patients. PDX models were established from primary breast tumors classified as MBC. PI3K-AKT-mTOR and RTK-MAPK pathway alterations were detected by targeted next-generation sequencing (NGS) and analyses of copy number alterations. Activation of the PI3K-AKT-mTOR and RTK-MAPK signaling pathways was analyzed with reverse-phase protein arrays (RPPA). PDXs carrying an activating mutation of PIK3CA and genomic changes to the RTK-MAPK signaling pathways were treated with a combination consisting of a PI3K inhibitor and a MEK inhibitor. Results In our clinical cohort, the patients with MBC had a worse prognosis than those with other histological subtypes. We established nine metaplastic TNBC PDXs. Three had a pathogenic mutation of PIK3CA and additional alterations to genes associated with RTK-MAPK signaling. The MBC PDXs expressed typical EMT and stem cell genes and were of the mesenchymal or mesenchymal stem-like TNBC subtypes. On histological analysis, MBC PDXs presented squamous or chondroid differentiation. RPPA analysis showed activation of the PI3K-AKT-mTOR and RTK-MAPK signaling pathways. In vivo, the combination of PI3K and MAPK inhibitors displayed marked antitumor activity in PDXs carrying genomic alterations of PIK3CA, AKT1, BRAF, and FGFR4. Conclusion The treatment of metaplastic breast cancer PDXs by activation of the PI3K-AKT-mTOR and RTK-MAPK pathways at the genomic and protein levels with a combination of PI3K and MEK inhibitors resulted in tumor regression in mutated models and may therefore be of interest for therapeutic purposes. Keywords: Metaplastic breast cancer, PI3K inhibitor, MEK inhibitor, Combination of targeted therapies
Metaplastic breast cancer (MBC) is a rare form of breast cancer characterized by an aggressive clinical presentation, with a poor response to standard chemotherapy. MBCs are typically triple-negative breast cancers (TNBCs), frequently with alterations to genes of the PI3K-AKT-mTOR and RTK-MAPK signaling pathways. The objective of this study was to determine the response to PI3K and MAPK pathway inhibitors in patient-derived xenografts (PDXs) of MBCs with targetable alterations. We compared survival between triple-negative MBCs and other histological subtypes, in a clinical cohort of 323 TNBC patients. PDX models were established from primary breast tumors classified as MBC. PI3K-AKT-mTOR and RTK-MAPK pathway alterations were detected by targeted next-generation sequencing (NGS) and analyses of copy number alterations. Activation of the PI3K-AKT-mTOR and RTK-MAPK signaling pathways was analyzed with reverse-phase protein arrays (RPPA). PDXs carrying an activating mutation of PIK3CA and genomic changes to the RTK-MAPK signaling pathways were treated with a combination consisting of a PI3K inhibitor and a MEK inhibitor. In our clinical cohort, the patients with MBC had a worse prognosis than those with other histological subtypes. We established nine metaplastic TNBC PDXs. Three had a pathogenic mutation of PIK3CA and additional alterations to genes associated with RTK-MAPK signaling. The MBC PDXs expressed typical EMT and stem cell genes and were of the mesenchymal or mesenchymal stem-like TNBC subtypes. On histological analysis, MBC PDXs presented squamous or chondroid differentiation. RPPA analysis showed activation of the PI3K-AKT-mTOR and RTK-MAPK signaling pathways. In vivo, the combination of PI3K and MAPK inhibitors displayed marked antitumor activity in PDXs carrying genomic alterations of PIK3CA, AKT1, BRAF, and FGFR4. The treatment of metaplastic breast cancer PDXs by activation of the PI3K-AKT-mTOR and RTK-MAPK pathways at the genomic and protein levels with a combination of PI3K and MEK inhibitors resulted in tumor regression in mutated models and may therefore be of interest for therapeutic purposes.
Abstract Background Metaplastic breast cancer (MBC) is a rare form of breast cancer characterized by an aggressive clinical presentation, with a poor response to standard chemotherapy. MBCs are typically triple-negative breast cancers (TNBCs), frequently with alterations to genes of the PI3K-AKT-mTOR and RTK-MAPK signaling pathways. The objective of this study was to determine the response to PI3K and MAPK pathway inhibitors in patient-derived xenografts (PDXs) of MBCs with targetable alterations. Methods We compared survival between triple-negative MBCs and other histological subtypes, in a clinical cohort of 323 TNBC patients. PDX models were established from primary breast tumors classified as MBC. PI3K-AKT-mTOR and RTK-MAPK pathway alterations were detected by targeted next-generation sequencing (NGS) and analyses of copy number alterations. Activation of the PI3K-AKT-mTOR and RTK-MAPK signaling pathways was analyzed with reverse-phase protein arrays (RPPA). PDXs carrying an activating mutation of PIK3CA and genomic changes to the RTK-MAPK signaling pathways were treated with a combination consisting of a PI3K inhibitor and a MEK inhibitor. Results In our clinical cohort, the patients with MBC had a worse prognosis than those with other histological subtypes. We established nine metaplastic TNBC PDXs. Three had a pathogenic mutation of PIK3CA and additional alterations to genes associated with RTK-MAPK signaling. The MBC PDXs expressed typical EMT and stem cell genes and were of the mesenchymal or mesenchymal stem-like TNBC subtypes. On histological analysis, MBC PDXs presented squamous or chondroid differentiation. RPPA analysis showed activation of the PI3K-AKT-mTOR and RTK-MAPK signaling pathways. In vivo, the combination of PI3K and MAPK inhibitors displayed marked antitumor activity in PDXs carrying genomic alterations of PIK3CA, AKT1, BRAF, and FGFR4. Conclusion The treatment of metaplastic breast cancer PDXs by activation of the PI3K-AKT-mTOR and RTK-MAPK pathways at the genomic and protein levels with a combination of PI3K and MEK inhibitors resulted in tumor regression in mutated models and may therefore be of interest for therapeutic purposes.
Background Metaplastic breast cancer (MBC) is a rare form of breast cancer characterized by an aggressive clinical presentation, with a poor response to standard chemotherapy. MBCs are typically triple-negative breast cancers (TNBCs), frequently with alterations to genes of the PI3K-AKT-mTOR and RTK-MAPK signaling pathways. The objective of this study was to determine the response to PI3K and MAPK pathway inhibitors in patient-derived xenografts (PDXs) of MBCs with targetable alterations. Methods We compared survival between triple-negative MBCs and other histological subtypes, in a clinical cohort of 323 TNBC patients. PDX models were established from primary breast tumors classified as MBC. PI3K-AKT-mTOR and RTK-MAPK pathway alterations were detected by targeted next-generation sequencing (NGS) and analyses of copy number alterations. Activation of the PI3K-AKT-mTOR and RTK-MAPK signaling pathways was analyzed with reverse-phase protein arrays (RPPA). PDXs carrying an activating mutation of PIK3CA and genomic changes to the RTK-MAPK signaling pathways were treated with a combination consisting of a PI3K inhibitor and a MEK inhibitor. Results In our clinical cohort, the patients with MBC had a worse prognosis than those with other histological subtypes. We established nine metaplastic TNBC PDXs. Three had a pathogenic mutation of PIK3CA and additional alterations to genes associated with RTK-MAPK signaling. The MBC PDXs expressed typical EMT and stem cell genes and were of the mesenchymal or mesenchymal stem-like TNBC subtypes. On histological analysis, MBC PDXs presented squamous or chondroid differentiation. RPPA analysis showed activation of the PI3K-AKT-mTOR and RTK-MAPK signaling pathways. In vivo, the combination of PI3K and MAPK inhibitors displayed marked antitumor activity in PDXs carrying genomic alterations of PIK3CA, AKT1, BRAF, and FGFR4. Conclusion The treatment of metaplastic breast cancer PDXs by activation of the PI3K-AKT-mTOR and RTK-MAPK pathways at the genomic and protein levels with a combination of PI3K and MEK inhibitors resulted in tumor regression in mutated models and may therefore be of interest for therapeutic purposes.
Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers
Metaplastic breast cancer (MBC) is a rare form of breast cancer characterized by an aggressive clinical presentation, with a poor response to standard chemotherapy. MBCs are typically triple-negative breast cancers (TNBCs), frequently with alterations to genes of the PI3K-AKT-mTOR and RTK-MAPK signaling pathways. The objective of this study was to determine the response to PI3K and MAPK pathway inhibitors in patient-derived xenografts (PDXs) of MBCs with targetable alterations. We compared survival between triple-negative MBCs and other histological subtypes, in a clinical cohort of 323 TNBC patients. PDX models were established from primary breast tumors classified as MBC. PI3K-AKT-mTOR and RTK-MAPK pathway alterations were detected by targeted next-generation sequencing (NGS) and analyses of copy number alterations. Activation of the PI3K-AKT-mTOR and RTK-MAPK signaling pathways was analyzed with reverse-phase protein arrays (RPPA). PDXs carrying an activating mutation of PIK3CA and genomic changes to the RTK-MAPK signaling pathways were treated with a combination consisting of a PI3K inhibitor and a MEK inhibitor. In our clinical cohort, the patients with MBC had a worse prognosis than those with other histological subtypes. We established nine metaplastic TNBC PDXs. Three had a pathogenic mutation of PIK3CA and additional alterations to genes associated with RTK-MAPK signaling. The MBC PDXs expressed typical EMT and stem cell genes and were of the mesenchymal or mesenchymal stem-like TNBC subtypes. On histological analysis, MBC PDXs presented squamous or chondroid differentiation. RPPA analysis showed activation of the PI3K-AKT-mTOR and RTK-MAPK signaling pathways. In vivo, the combination of PI3K and MAPK inhibitors displayed marked antitumor activity in PDXs carrying genomic alterations of PIK3CA, AKT1, BRAF, and FGFR4. The treatment of metaplastic breast cancer PDXs by activation of the PI3K-AKT-mTOR and RTK-MAPK pathways at the genomic and protein levels with a combination of PI3K and MEK inhibitors resulted in tumor regression in mutated models and may therefore be of interest for therapeutic purposes.
ArticleNumber 13
Audience Academic
Author Briaux, A
Dahmani, A
Painsec, P
Chateau-Joubert, S
Marangoni, E
Melaabi, S
Coussy, F
Montaudon, E
El Botty, R
Fuhrmann, L
Vacher, S
de Koning, L
Morisset, L
Lavigne, M
Larcher, T
Huguet, L
Salomon, A Vincent
Sourd, L
Bieche, I
Gu, C
Author_xml – sequence: 1
  givenname: F
  orcidid: 0000-0002-6443-8883
  surname: Coussy
  fullname: Coussy, F
  email: florence.coussy@curie.fr, florence.coussy@curie.fr, florence.coussy@curie.fr
  organization: Department of Medical Oncology, Institut Curie, Paris, France. florence.coussy@curie.fr
– sequence: 2
  givenname: R
  surname: El Botty
  fullname: El Botty, R
  organization: Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France
– sequence: 3
  givenname: M
  surname: Lavigne
  fullname: Lavigne, M
  organization: Department of Biopathology, Institut Curie, Paris, France
– sequence: 4
  givenname: C
  surname: Gu
  fullname: Gu, C
  organization: Department of Biopathology, Institut Curie, Paris, France
– sequence: 5
  givenname: L
  surname: Fuhrmann
  fullname: Fuhrmann, L
  organization: Department of Biopathology, Institut Curie, Paris, France
– sequence: 6
  givenname: A
  surname: Briaux
  fullname: Briaux, A
  organization: Unit of Pharmacogenomics, Department of Genetics, Institut Curie, Paris, France
– sequence: 7
  givenname: L
  surname: de Koning
  fullname: de Koning, L
  organization: Translational Research Department, RPPA Platform, Institut Curie Research Center, Paris, France
– sequence: 8
  givenname: A
  surname: Dahmani
  fullname: Dahmani, A
  organization: Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France
– sequence: 9
  givenname: E
  surname: Montaudon
  fullname: Montaudon, E
  organization: Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France
– sequence: 10
  givenname: L
  surname: Morisset
  fullname: Morisset, L
  organization: Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France
– sequence: 11
  givenname: L
  surname: Huguet
  fullname: Huguet, L
  organization: Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France
– sequence: 12
  givenname: L
  surname: Sourd
  fullname: Sourd, L
  organization: Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France
– sequence: 13
  givenname: P
  surname: Painsec
  fullname: Painsec, P
  organization: Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France
– sequence: 14
  givenname: S
  surname: Chateau-Joubert
  fullname: Chateau-Joubert, S
  organization: BioPôle Alfort, National Veterinary School of Alfort, Maison Alfort, France
– sequence: 15
  givenname: T
  surname: Larcher
  fullname: Larcher, T
  organization: INRA, APEX-PAnTher, Oniris, Nantes, France
– sequence: 16
  givenname: S
  surname: Vacher
  fullname: Vacher, S
  organization: Unit of Pharmacogenomics, Department of Genetics, Institut Curie, Paris, France
– sequence: 17
  givenname: S
  surname: Melaabi
  fullname: Melaabi, S
  organization: Unit of Pharmacogenomics, Department of Genetics, Institut Curie, Paris, France
– sequence: 18
  givenname: A Vincent
  surname: Salomon
  fullname: Salomon, A Vincent
  organization: Department of Biopathology, Institut Curie, Paris, France
– sequence: 19
  givenname: E
  surname: Marangoni
  fullname: Marangoni, E
  organization: Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie Research Center, Paris, France
– sequence: 20
  givenname: I
  surname: Bieche
  fullname: Bieche, I
  organization: Inserm U1016, University Paris Descartes, Paris, France
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32087759$$D View this record in MEDLINE/PubMed
https://hal.science/hal-02508763$$DView record in HAL
BookMark eNptUl2LEzEUHWTF_dAf4IsEBMGHWfPRSWZehFJXt7TiPij4FvLZpswkNZlZqL_ejLOurUggudycc5J777ksznzwpiheIniNUE3fJUTgrCohhiWsZ7Q8PCkuEKtoWTOMz47i8-IypR2EFDUYPivOCYY1Y1VzUfxchE46L3oXPAgW3C3JCgivweebFXB-66TrQ0zg4EyrE9BDFLI1IJrOpTRynAd3H76DLmjTpklhRRbzsht60RsNOtOLfStS7xSQ0eQAKOGViel58dSKNpkXD-dV8e3jzdfFbbn-8mm5mK9LRXHVl00tVEUxpFgqrZjQFgtMiKlgI4UVEhmlKUIK24aZRqq8QcuqStsG1mJWk6tiOenqIHZ8H10n4oEH4fjvRIgbLmL-Xmu4kjY3iUFspJxp0jRohhUW1GZtQhDMWu8nrf0gO6OV8X0U7Yno6Y13W74J95xBQlE9CrydBLb_0G7naz7mIK7ybCi5Rxn7-uGxGH4MJvV8F4boc684JiwPMMPoX9RG5AqctyE_rPJ4FJ9TRGfZKYxl1PV_UHnpPEmVbWVdzp8Q3hwRtka0_TaFdhiNkk6BaAKqGFKKxj6WhSAfbconm-bKIB9tyg-Z8-q4jY-MP74kvwA8f-Lx
CitedBy_id crossref_primary_10_1002_adfm_202100088
crossref_primary_10_3390_jpm13040673
crossref_primary_10_1016_j_critrevonc_2023_103924
crossref_primary_10_2147_BCTT_S296784
crossref_primary_10_1016_j_tranon_2024_101893
crossref_primary_10_1186_s13045_020_00949_4
crossref_primary_10_1016_j_bbagrm_2023_194988
crossref_primary_10_1101_mcs_a006255
crossref_primary_10_1186_s12967_023_04841_w
crossref_primary_10_1038_s41467_021_25650_z
crossref_primary_10_3390_cells11162508
crossref_primary_10_1016_j_breast_2022_10_012
crossref_primary_10_1186_s40364_020_00247_8
crossref_primary_10_1007_s10637_023_01357_4
crossref_primary_10_1186_s13045_022_01278_4
crossref_primary_10_1016_j_semcancer_2021_06_019
crossref_primary_10_1016_j_cpccr_2023_100239
crossref_primary_10_1111_cas_16208
crossref_primary_10_1007_s10549_023_06945_9
crossref_primary_10_1007_s12032_023_02259_4
crossref_primary_10_1186_s12935_023_02953_3
crossref_primary_10_1186_s13058_022_01521_3
crossref_primary_10_1002_cam4_6176
crossref_primary_10_1158_1078_0432_CCR_21_0714
crossref_primary_10_3390_ph16020244
crossref_primary_10_1038_s41392_023_01419_2
crossref_primary_10_1038_s41467_021_26502_6
Cites_doi 10.1038/s41523-017-0048-0
10.1002/path.5184
10.1093/bioinformatics/btp624
10.1245/s10434-006-9124-7
10.1016/j.tibs.2011.03.006
10.1007/s10549-008-0197-9
10.1093/bioinformatics/bti113
10.1002/ijc.32266
10.1016/j.humpath.2018.11.023
10.1158/1078-0432.CCR-17-3490
10.1038/modpathol.2014.142
10.1038/bjc.2015.60
10.1016/j.molonc.2013.02.004
10.4137/CIN.S9983
10.1111/pcmr.12577
10.1093/clinchem/45.8.1148
10.1093/biostatistics/kxh008
10.1038/bjc.2017.131
10.1023/A:1008329910362
10.1038/nrc3637
10.1158/0008-5472.CAN-08-3441
10.1158/2159-8290.CD-12-0095
10.1245/s10434-018-6533-3
10.5858/arpa.2014-0200-OA
10.1158/1078-0432.CCR-07-0078
10.1186/gb-2011-12-4-r41
10.7150/jca.22280
10.1016/j.cell.2018.03.035
10.1038/s41379-018-0081-z
10.1016/j.humpath.2009.11.013
10.1158/0008-5472.CAN-12-1470
10.1126/scisignal.2004088
10.1007/s10549-011-1686-9
10.1093/jnci/djp235
10.1038/modpathol.2011.167
10.1016/j.jfma.2018.12.004
10.1158/1078-0432.CCR-16-2857
10.1186/1471-2164-11-256
ContentType Journal Article
Copyright COPYRIGHT 2020 BioMed Central Ltd.
2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Distributed under a Creative Commons Attribution 4.0 International License
The Author(s). 2020
Copyright_xml – notice: COPYRIGHT 2020 BioMed Central Ltd.
– notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: Distributed under a Creative Commons Attribution 4.0 International License
– notice: The Author(s). 2020
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7T5
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
1XC
VOOES
5PM
DOA
DOI 10.1186/s13045-020-0846-y
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Immunology Abstracts
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Medical Database
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Hyper Article en Ligne (HAL)
Hyper Article en Ligne (HAL) (Open Access)
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Publicly Available Content Database
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
AIDS and Cancer Research Abstracts
Immunology Abstracts
ProQuest One Academic
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
DatabaseTitleList
MEDLINE

Publicly Available Content Database



Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1756-8722
EndPage 10
ExternalDocumentID oai_doaj_org_article_cbf006702ebb4d399142c2a6ff973310
oai_HAL_hal_02508763v1
A616411877
10_1186_s13045_020_0846_y
32087759
Genre Research Support, Non-U.S. Gov't
Journal Article
Report
GeographicLocations United States
France
GeographicLocations_xml – name: United States
– name: France
GrantInformation_xml – fundername: ;
  grantid: PhD allocation
– fundername: ;
  grantid: 4FI13229SREX
GroupedDBID ---
-5E
-5G
-A0
-BR
0R~
2WC
3V.
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
ABDBF
ABUWG
ACGFS
ACIHN
ACPRK
ACRMQ
ADBBV
ADINQ
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C24
C6C
CCPQU
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBD
EBLON
EBS
ECM
EIF
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IEA
IHR
IHW
INH
INR
ITC
KQ8
M1P
M48
M~E
NPM
O5R
O5S
OK1
P2P
PGMZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
~8M
AAYXX
CITATION
AFGXO
7T5
7XB
8FK
AZQEC
DWQXO
H94
K9.
PQEST
PQUKI
PRINS
1XC
2VQ
4.4
AHSBF
EJD
H13
IPNFZ
RIG
VOOES
5PM
ID FETCH-LOGICAL-c625t-98ac562062bcdc7adf2a233e509bafab1ecd611c2f97e9bc7e90f755df908a483
IEDL.DBID RPM
ISSN 1756-8722
IngestDate Tue Oct 22 15:15:25 EDT 2024
Tue Sep 17 21:10:49 EDT 2024
Tue Oct 15 14:49:14 EDT 2024
Mon Nov 18 14:56:02 EST 2024
Tue Nov 19 20:55:51 EST 2024
Tue Nov 12 23:30:41 EST 2024
Tue Aug 20 21:58:44 EDT 2024
Thu Nov 21 20:45:48 EST 2024
Sat Sep 28 08:35:35 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords MEK inhibitor
Metaplastic breast cancer
Combination of targeted therapies
PI3K inhibitor
Language English
License Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c625t-98ac562062bcdc7adf2a233e509bafab1ecd611c2f97e9bc7e90f755df908a483
ORCID 0000-0002-6443-8883
0000-0002-2430-5429
0000-0002-0042-6023
0000-0002-0396-3190
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036180/
PMID 32087759
PQID 2378777636
PQPubID 54946
PageCount 10
ParticipantIDs doaj_primary_oai_doaj_org_article_cbf006702ebb4d399142c2a6ff973310
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7036180
hal_primary_oai_HAL_hal_02508763v1
proquest_journals_2378777636
gale_infotracmisc_A616411877
gale_infotracacademiconefile_A616411877
gale_healthsolutions_A616411877
crossref_primary_10_1186_s13045_020_0846_y
pubmed_primary_32087759
PublicationCentury 2000
PublicationDate 2020-02-22
PublicationDateYYYYMMDD 2020-02-22
PublicationDate_xml – month: 02
  year: 2020
  text: 2020-02-22
  day: 22
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Journal of hematology and oncology
PublicationTitleAlternate J Hematol Oncol
PublicationYear 2020
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References CH Mermel (846_CR28) 2011; 12
Y Zhang (846_CR34) 2012; 25
AE McCart Reed (846_CR1) 2019; 247
X Chen (846_CR21) 2012; 11
IC Chen (846_CR6) 2011; 130
E Cerami (846_CR26) 2012; 2
J Gao (846_CR25) 2013; 6
F Cardoso (846_CR8) 2009; 101
BT Hennessy (846_CR11) 2009; 69
CM Pezzi (846_CR4) 2007; 14
B Weigelt (846_CR2) 2014; 14
I Bieche (846_CR31) 2001; 61
F Coussy (846_CR22) 2019; 145
S Rondeau (846_CR33) 2015; 112
R Crepin (846_CR24) 2017; 30
OC Lingjaerde (846_CR29) 2005; 21
I Bieche (846_CR32) 1999; 45
B Weigelt (846_CR3) 2009; 117
F Coussy (846_CR17) 2017; 116
C Laurent (846_CR23) 2013; 7
E Marangoni (846_CR18) 2007; 13
E Marangoni (846_CR16) 2018; 24
D Rayson (846_CR7) 1999; 10
HY Liao (846_CR35) 2018; 9
CT Ong (846_CR9) 2018; 25
CKY Ng (846_CR13) 2017; 23
G Krings (846_CR15) 2018; 31
T Popova (846_CR30) 2012; 72
MC Mendoza (846_CR39) 2011; 36
J Zhai (846_CR36) 2019; 86
F Sanchez-Vega (846_CR38) 2018; 173
MH Yang (846_CR37) 2019; 118
BS Carvalho (846_CR19) 2010; 26
N Okada (846_CR5) 2010; 41
B Weigelt (846_CR10) 2015; 28
S Piscuoglio (846_CR12) 2017; 3
AL Samuels (846_CR20) 2010; 11
AB Olshen (846_CR27) 2004; 5
JS Ross (846_CR14) 2015; 139
References_xml – volume: 3
  start-page: 48
  year: 2017
  ident: 846_CR12
  publication-title: NPJ Breast Cancer.
  doi: 10.1038/s41523-017-0048-0
  contributor:
    fullname: S Piscuoglio
– volume: 247
  start-page: 214
  issue: 2
  year: 2019
  ident: 846_CR1
  publication-title: J Pathol.
  doi: 10.1002/path.5184
  contributor:
    fullname: AE McCart Reed
– volume: 26
  start-page: 242
  issue: 2
  year: 2010
  ident: 846_CR19
  publication-title: Bioinformatics.
  doi: 10.1093/bioinformatics/btp624
  contributor:
    fullname: BS Carvalho
– volume: 14
  start-page: 166
  issue: 1
  year: 2007
  ident: 846_CR4
  publication-title: Ann Surg Oncol.
  doi: 10.1245/s10434-006-9124-7
  contributor:
    fullname: CM Pezzi
– volume: 36
  start-page: 320
  year: 2011
  ident: 846_CR39
  publication-title: Trends Biochem Sci.
  doi: 10.1016/j.tibs.2011.03.006
  contributor:
    fullname: MC Mendoza
– volume: 117
  start-page: 273
  issue: 2
  year: 2009
  ident: 846_CR3
  publication-title: Breast Cancer Res Treat.
  doi: 10.1007/s10549-008-0197-9
  contributor:
    fullname: B Weigelt
– volume: 21
  start-page: 821
  issue: 6
  year: 2005
  ident: 846_CR29
  publication-title: Bioinformatics.
  doi: 10.1093/bioinformatics/bti113
  contributor:
    fullname: OC Lingjaerde
– volume: 145
  start-page: 1902
  issue: 7
  year: 2019
  ident: 846_CR22
  publication-title: Int J Cancer.
  doi: 10.1002/ijc.32266
  contributor:
    fullname: F Coussy
– volume: 86
  start-page: 85
  year: 2019
  ident: 846_CR36
  publication-title: Hum Pathol.
  doi: 10.1016/j.humpath.2018.11.023
  contributor:
    fullname: J Zhai
– volume: 24
  start-page: 2605
  issue: 11
  year: 2018
  ident: 846_CR16
  publication-title: Clin Cancer Res.
  doi: 10.1158/1078-0432.CCR-17-3490
  contributor:
    fullname: E Marangoni
– volume: 61
  start-page: 1652
  issue: 4
  year: 2001
  ident: 846_CR31
  publication-title: Cancer Res.
  contributor:
    fullname: I Bieche
– volume: 28
  start-page: 340
  issue: 4
  year: 2015
  ident: 846_CR10
  publication-title: Mod Pathol.
  doi: 10.1038/modpathol.2014.142
  contributor:
    fullname: B Weigelt
– volume: 112
  start-page: 1059
  year: 2015
  ident: 846_CR33
  publication-title: Br J Cancer.
  doi: 10.1038/bjc.2015.60
  contributor:
    fullname: S Rondeau
– volume: 7
  start-page: 625
  issue: 3
  year: 2013
  ident: 846_CR23
  publication-title: Mol Oncol.
  doi: 10.1016/j.molonc.2013.02.004
  contributor:
    fullname: C Laurent
– volume: 11
  start-page: 147
  year: 2012
  ident: 846_CR21
  publication-title: Cancer Inform.
  doi: 10.4137/CIN.S9983
  contributor:
    fullname: X Chen
– volume: 30
  start-page: 317
  issue: 3
  year: 2017
  ident: 846_CR24
  publication-title: Pigment Cell Melanoma Res
  doi: 10.1111/pcmr.12577
  contributor:
    fullname: R Crepin
– volume: 45
  start-page: 1148
  year: 1999
  ident: 846_CR32
  publication-title: Clin Chem.
  doi: 10.1093/clinchem/45.8.1148
  contributor:
    fullname: I Bieche
– volume: 5
  start-page: 557
  issue: 4
  year: 2004
  ident: 846_CR27
  publication-title: Biostatistics
  doi: 10.1093/biostatistics/kxh008
  contributor:
    fullname: AB Olshen
– volume: 116
  start-page: 1595
  issue: 12
  year: 2017
  ident: 846_CR17
  publication-title: Br J Cancer.
  doi: 10.1038/bjc.2017.131
  contributor:
    fullname: F Coussy
– volume: 10
  start-page: 413
  issue: 4
  year: 1999
  ident: 846_CR7
  publication-title: Ann Oncol.
  doi: 10.1023/A:1008329910362
  contributor:
    fullname: D Rayson
– volume: 14
  start-page: 147
  issue: 3
  year: 2014
  ident: 846_CR2
  publication-title: Nat Rev Cancer.
  doi: 10.1038/nrc3637
  contributor:
    fullname: B Weigelt
– volume: 69
  start-page: 4116
  issue: 10
  year: 2009
  ident: 846_CR11
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-08-3441
  contributor:
    fullname: BT Hennessy
– volume: 2
  start-page: 401
  year: 2012
  ident: 846_CR26
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-12-0095
  contributor:
    fullname: E Cerami
– volume: 25
  start-page: 2249
  issue: 8
  year: 2018
  ident: 846_CR9
  publication-title: Ann Surg Oncol.
  doi: 10.1245/s10434-018-6533-3
  contributor:
    fullname: CT Ong
– volume: 139
  start-page: 642
  issue: 5
  year: 2015
  ident: 846_CR14
  publication-title: Arch Pathol Lab Med.
  doi: 10.5858/arpa.2014-0200-OA
  contributor:
    fullname: JS Ross
– volume: 13
  start-page: 3989
  issue: 13
  year: 2007
  ident: 846_CR18
  publication-title: Clin Cancer Res.
  doi: 10.1158/1078-0432.CCR-07-0078
  contributor:
    fullname: E Marangoni
– volume: 12
  start-page: R41
  issue: 4
  year: 2011
  ident: 846_CR28
  publication-title: Genome Biol
  doi: 10.1186/gb-2011-12-4-r41
  contributor:
    fullname: CH Mermel
– volume: 9
  start-page: 296
  issue: 2
  year: 2018
  ident: 846_CR35
  publication-title: J Cancer.
  doi: 10.7150/jca.22280
  contributor:
    fullname: HY Liao
– volume: 173
  start-page: 321
  year: 2018
  ident: 846_CR38
  publication-title: Cell.
  doi: 10.1016/j.cell.2018.03.035
  contributor:
    fullname: F Sanchez-Vega
– volume: 31
  start-page: 1661
  issue: 11
  year: 2018
  ident: 846_CR15
  publication-title: Mod Pathol.
  doi: 10.1038/s41379-018-0081-z
  contributor:
    fullname: G Krings
– volume: 41
  start-page: 960
  issue: 10
  year: 2010
  ident: 846_CR5
  publication-title: Hum Pathol.
  doi: 10.1016/j.humpath.2009.11.013
  contributor:
    fullname: N Okada
– volume: 72
  start-page: 5454
  year: 2012
  ident: 846_CR30
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-12-1470
  contributor:
    fullname: T Popova
– volume: 6
  start-page: 269
  year: 2013
  ident: 846_CR25
  publication-title: Sci Signal
  doi: 10.1126/scisignal.2004088
  contributor:
    fullname: J Gao
– volume: 130
  start-page: 345
  issue: 1
  year: 2011
  ident: 846_CR6
  publication-title: Breast Cancer Res Treat.
  doi: 10.1007/s10549-011-1686-9
  contributor:
    fullname: IC Chen
– volume: 101
  start-page: 1174
  issue: 17
  year: 2009
  ident: 846_CR8
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djp235
  contributor:
    fullname: F Cardoso
– volume: 25
  start-page: 178
  issue: 2
  year: 2012
  ident: 846_CR34
  publication-title: Mod Pathol
  doi: 10.1038/modpathol.2011.167
  contributor:
    fullname: Y Zhang
– volume: 118
  start-page: 1333
  year: 2019
  ident: 846_CR37
  publication-title: J Formos Med Assoc.
  doi: 10.1016/j.jfma.2018.12.004
  contributor:
    fullname: MH Yang
– volume: 23
  start-page: 3859
  issue: 17
  year: 2017
  ident: 846_CR13
  publication-title: Clin Cancer Res.
  doi: 10.1158/1078-0432.CCR-16-2857
  contributor:
    fullname: CKY Ng
– volume: 11
  start-page: 256
  year: 2010
  ident: 846_CR20
  publication-title: BMC Genomics.
  doi: 10.1186/1471-2164-11-256
  contributor:
    fullname: AL Samuels
SSID ssj0061920
Score 2.4357176
Snippet Metaplastic breast cancer (MBC) is a rare form of breast cancer characterized by an aggressive clinical presentation, with a poor response to standard...
Background Metaplastic breast cancer (MBC) is a rare form of breast cancer characterized by an aggressive clinical presentation, with a poor response to...
Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers
Abstract Background Metaplastic breast cancer (MBC) is a rare form of breast cancer characterized by an aggressive clinical presentation, with a poor response...
SourceID doaj
pubmedcentral
hal
proquest
gale
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 13
SubjectTerms 1-Phosphatidylinositol 3-kinase
Adult
Aged
Aged, 80 and over
Animals
Antineoplastic Agents - therapeutic use
Arrays
Biotechnology industries
Breast cancer
Breast tumors
Cancer treatment
Chemotherapy
Class I Phosphatidylinositol 3-Kinases - antagonists & inhibitors
Class I Phosphatidylinositol 3-Kinases - genetics
Class I Phosphatidylinositol 3-Kinases - metabolism
Combination of targeted therapies
Comparative analysis
Gene expression
Genes
Genomes
Genomics
Hematology
Humans
Kinases
Life Sciences
MEK inhibitor
MEK inhibitors
Metaplastic breast cancer
Metastasis
Mice, Nude
Middle Aged
Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors
Mitogen-Activated Protein Kinase Kinases - metabolism
Mutation
Mutation - drug effects
Oncology
Patients
Phosphatidylinositol 3-Kinases - metabolism
Phosphoinositide-3 Kinase Inhibitors - therapeutic use
PI3K inhibitor
Protein Kinase Inhibitors - therapeutic use
Proteins
Proto-Oncogene Proteins c-akt - metabolism
Remission
Short Report
Signal Transduction - drug effects
Stem cells
TOR Serine-Threonine Kinases - metabolism
Triple Negative Breast Neoplasms - drug therapy
Triple Negative Breast Neoplasms - genetics
Triple Negative Breast Neoplasms - metabolism
Tumors
Xenograft Model Antitumor Assays
Xenografts
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELZgD4gL4k1gAQshISFZGzux4xzLsqtCKdoDK_Vm-RW1h82u2hSp_HpmnLTawIELlx6SkZPOw54vHn9DyPuSO1dC4s20k5KVvtbMFZEzWQUeFKBtmSjz59_V9LL8upCLW62-sCaspwfuFXfiXZPOkogIgwZYTnkpvLCqaWpsN9ij9VzswVQ_ByMq2O9hcq1ONhw3BBlCpRwWXLYbrUKJrP8wJd9dYkXk3-nmn1WTt5ah84fkwZA_0kn_3o_Indg-Jvfmww75E_ILAhzAbtI3vW7oxZdiRm0b6PxsRlftcuVW2F-H7rBybUPDdo1np-ga277hhzOQoRefFzR1yNn0I8yK0wm72mJaGuhV7OwNpNzwfOqwor2jHj1nvXlKLs_PfpxO2dBfgXlAPR2rtfWQ_uRKOB98ZUMjrCiKCDmEs411PPqgOPcCVB1r5-EnbyopQ1Pn2pa6eEaO2us2viBUFtJB8qh8kIC1rbYQ5qUIiOi0zXnMyMe9vs1NT6NhEvzQyvTGMWAcg8Yxu4x8QoscBJEBO10AvzCDX5h_-UVG3qI9TX-c9BDHZqIAIGKP9SojH5IERjIY1NvhQAL8I-TEGkkejyTBIn50-x34zOh1p5NvBq9hhomcfz85jLF3KTNMExsjigr5GFWhMvK8967DMIVArkZZZ6Qa-d3oOeM77WqZCMKRVI3r_OX_0OMrcl-kuBFMiGNy1K238TXkYZ17k0LuN2X9LJw
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bi9NAFB7cLogv4t3oqoMIgjBsZiaXyZN01y7V2qWIC_s2zCWxfdi0Nq1Qf73nTNJqFHzJQ3KYSXIu8525fIeQNwm3NgHgzZRNU5a4QjErS87S3HOfQbadBsr86WU2vko-XafX3YRb022r3MfEEKj90uEc-amQOVLXZTJ7v_rOsGoUrq52JTSOyLHgUqkBOT4bXc6-7GMxZgf7tUyustOG48Igw5QphoGX7XqjUSDtP4TmoznujPwXdv69e_KP4ejiHrnb4Ug6bBV_n9wq6wfk9rRbKX9IfoKjQ9Ib_jtdVnT2UU6oqT2djiZ0Uc8XdoF1dugOd7A11G_XeIaKrrH8G06ggQydfbimoVJO07YwkedDdrNFeOrpTbkxK4De0D-1uLN9Qx1a0Lp5RK4uRl_Px6yrs8AcZD8bVijjAAbFmbDOu9z4ShghZQlYwprKWF46n3HuRFXkZWEdXOIqT1NfFbEyiZKPyaBe1uVTQlOZWgCRmfMp5NxGGXD3RHjM7JSJeRmRd_v_rVctnYYOaYjKdKscDcrRqBy9i8gZauQgiEzY4cZy_U13jqWdrcJZI1GC0XmAWzwRTpisgpeVgF0j8gr1qdtjpQd_1sMMEkWstZ5H5G2QQI8GhTrTHUyAL0JurJ7kSU8SNOJ6j1-DzfRedzz8rPEeIk3k_vvBoY29SekuXDT6t3FH5ElrXYdmpEDOxrSISN6zu14__Sf1Yh6IwpFcjav42f-7fE7uiOARgglxQgab9bZ8AUhrY1927vQL2BomBg
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3db9MwELe2ISFeEN8LG2AhJCQkQ-zETvKAUBmbCqVoD1Tqm-WPhFZi6Za2iPLXc-ekFYFJvPQhOTmp787-_eL7IORFyq1NAXiz3ErJUlfkzCYlZzLz3Ctg2zKUzB9_UcNJ-mkqp3tk296qm8DltdQO-0lNmu-vf15t3oHDvw0On6s3S47HfQyJUAzbKdvskxsCNkaM8Bqnu0MFpAptfqRUsAgI0R1yXjtEb5sK1fx3a_b-DEMm_8Wjf4dV_rFPnd0htzuASQetRdwle2V9j9wcd0fo98kvWAGADQeF0EVFzz8mI2pqT8enIzqvZ3M7xwY8dIOhbUvq1w0mV9EG-8LhlzWQoecfpjS00Fm2I4ySkwG7WCNu9fSiXJlLwOTwfGox5H1FHZpWs3xAJmenX0-GrGvAwBzQohUrcuMAH8VKWOddZnwljEiSEkCGNZWxvHRece5EVWRlYR38xFUmpa-KODdpnjwkB_WiLg8JlYm0gC6V8xLIuMkNrAOp8Ej5chPzMiKvtvOtL9s6Gzrwk1zpVjkalKNROXoTkfeokZ0glsgOFxbNN915nHa2CklIogRr9IDDeCqcMKqCl00A1EbkGepTt_mmO0fXAwUMEpuwZxF5GSTQ-EChznQZC_CPsGhWT_K4Jwkacb3bz8Fmeq87HHzWeA0hKBYF_MFhjK1J6a0baJFkWLBRJSoij1rr2g2TCCzmKIuIZD276z2nf6eez0IFcay6xvP48X-n4IjcEsEpBBPimBysmnX5BFDYyj4NvvUbty8qvw
  priority: 102
  providerName: Scholars Portal
Title Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers
URI https://www.ncbi.nlm.nih.gov/pubmed/32087759
https://www.proquest.com/docview/2378777636
https://hal.science/hal-02508763
https://pubmed.ncbi.nlm.nih.gov/PMC7036180
https://doaj.org/article/cbf006702ebb4d399142c2a6ff973310
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdNB6UvY99z22ViDAYDN7Fk2c6jm6VkyVLCtkLehD7sJbA4IR-D7K_fnWyHenvbiwP2RZZ9d9LvrLufCHkfBlqHALz9RAvhh6aX-JpngS9iG9gIom3hKPMnd9HwPhzNxOyEiLoWxiXtG724Ln4ur4vF3OVWrpemU-eJdaaTPpJGYYlyi7Rg-q1D9HL4xYCgXr4MkqizDXAt0McoqQtzrX84J2ecIQ0e0pM-mIscZf9xYG7NMS_yX9D5d-7kg8no9gl5XKFImpa9fUpOsuIZOZtU6-TPyW9wcwh53Vunq5xOP_MxVYWlk8GYLor5Qi9wlx16wPy1LbX7DVZQ0Q1u_oafz0CGTj_NqNsnZ1u2MOb91F_uEZxausx2ag3AG-5PNea176hB-9lsX5D728H3_tCvdlnwDcQ-O7-XKAMgqBsxbayJlc2ZYpxngCS0ypUOMmOjIDAs78VZTxs4dPNYCJv3uokKE_6SnBarIntNqOBCA4SMjBUQcatEgbOHzGJcl6hukHnkY_2-5bok05AuCEkiWepJgp4k6kkePHKDGjkKIg-2O7Ha_JCVNUijc1dpxDIwOQtgKwiZYSrKobMckKtH3qI-ZVlUevRmmUYQJuJO67FHPjgJ9GdQqFFVWQI8ETJjNSSvGpKgEdO4_A5sptHdYfpF4jnEmcj89yuANmqTktVgsZWMx8jKGPHII69K6zo2U5uqR-KG3TXu07wCXuNowisvufjvf16Sc-b8hvmMXZHT3WafvQEIttNtcLxZ3CaP0nT0bQS_N4O76de2-6ABx0mYtJ1T_gHizTNR
link.rule.ids 230,314,727,780,784,864,885,2102,12056,21388,24318,27924,27925,31719,33744,43310,43805,53791,53793
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bi9NAFB7cLqgv4nWNru4ggiAMm5lkcnmS7tqlay8U2YW-DXNJbB82rUkr1F_vOUlajYIveUgOM0nOZb4zl-8Q8j7kxoQAvFlipGShTRNmgowzGTvuIsi2ZU2ZP5lGw9vwy1zO2wm3qt1WuY-JdaB2K4tz5OciiJG6LgqiT-vvDKtG4epqW0LjiBwjc7rskeOLwXT2dR-LMTvYr2XyJDqvOC4MMkyZfBh42a4zGtWk_YfQfLTAnZH_ws6_d0_-MRxdPSaPWhxJ-43in5B7WfGU3J-0K-XPyE9wdEh66_9OVzmdXQcjqgtHJ4MRXRaLpVlinR26wx1sFXXbEs9Q0RLLv-EEGsjQ2ec5rSvlVE0Lo-Cyz-62CE8dvcs2eg3QG_qnBne2b6hFCyqr5-T2anBzOWRtnQVmIfvZsDTRFmCQHwljnY21y4UWQZABljA614Zn1kWcW5GncZYaCxc_j6V0eeonOkyCF6RXrIrsJaEykAZAZGSdhJxbJxrcPRQOM7tE-zzzyMf9_1brhk5D1WlIEqlGOQqUo1A5aueRC9TIQRCZsOsbq_Kbah1LWZPXZ41EBkbnAG7xUFihoxxeNgDs6pEz1KdqjpUe_Fn1I0gUsdZ67JEPtQR6NCjU6vZgAnwRcmN1JE87kqAR23n8Dmym87rD_ljhPUSayP33g0Mbe5NSbbio1G_j9shJY12HZgKBnI0y9UjcsbtOP90nxXJRE4UjuRpP_Ff_7_KMPBjeTMZqfD0dvSYPRe0dgglxSnqbcpu9AdS1MW9b1_oFuVoo7g
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9owELfWTkJ9mfa9dN1qTZMmTXIhduKER0aL6CgVD6vEm-WPZCCNgPioxP763TkJItvbXnhIDsfk7uzf4bvfEfI5Co2JAHiz1MQxi2w3ZUZkIYsTFzoJ0XbsKfPH93L4EH2fxtOjVl8-ad-a-VXxa3FVzGc-t3K1sO06T6w9GfeRNApLlFcub5-Qp7EAI6sD9XIRxrCgPsQMU9nehHgiyDBW6sCOy_ZnpCU4kuEhSenRjuSJ-w_L88kMsyP_hZ5_Z1AebUmD5-RZhSVpr5zzC_IkK16S1rg6LX9FfoOzQ-Dr3z1d5nRyK0ZUF46Ob0Z0XszmZo69duges9g21O3WWEdF19gCDv9EAxk6uZ5S3y1nU44wEv0eW-wQojq6yLZ6BfAbnk8NZrdvqUUrWm9ek4fBzY_-kFW9FpiFCGjLuqm2AIU6khvrbKJdzjUXIgM8YXSuTZhZJ8PQ8rybZF1j4aOTJ3Hs8m4n1VEq3pDTYllk7wiNRWwASErrYoi7darB5SPuMLpLdSfMAvK1ft9qVVJqKB-KpFKVelKgJ4V6UvuAfEONHASRDdtfWK5_qsomlDW5rzfiGRieA8gVRtxyLXOYrAD8GpBL1KcqS0sPPq16EoJF7LeeBOSLl0CvBoVaXRUnwC9CfqyG5EVDEjRiG7c_gc00pjvs3Sm8hmgT-f8eQxijNilVLRkbxUWC3IxSyIC8La3rMExtqgFJGnbXeE7zDviOJwuvfOX8v795SVqT64G6u70fvSdn3LsQZ5xfkNPtepd9AEy2NR-99_0By6Ax3Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Combination+of+PI3K+and+MEK+inhibitors+yields+durable+remission+in+PDX+models+of+PIK3CA-mutated+metaplastic+breast+cancers&rft.jtitle=Journal+of+hematology+and+oncology&rft.au=Sourd%2C+L&rft.au=Huguet%2C+L&rft.au=Melaabi%2C+S&rft.au=Morisset%2C+L&rft.date=2020-02-22&rft.pub=BioMed+Central+Ltd&rft.issn=1756-8722&rft.eissn=1756-8722&rft.volume=13&rft.issue=1&rft_id=info:doi/10.1186%2Fs13045-020-0846-y&rft.externalDBID=n%2Fa&rft.externalDocID=A616411877
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-8722&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-8722&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-8722&client=summon